Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vericiguat (BAY1021189) 是一种有效的口服鸟苷酸环化酶刺激剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 552 | 现货 | ||
2 mg | ¥ 792 | 现货 | ||
5 mg | ¥ 1,350 | 现货 | ||
10 mg | ¥ 2,150 | 现货 | ||
25 mg | ¥ 3,630 | 现货 | ||
50 mg | ¥ 5,250 | 现货 | ||
100 mg | ¥ 7,390 | 现货 | ||
500 mg | ¥ 14,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,530 | 现货 |
产品描述 | Vericiguat (BAY1021189) is a potent and orally available guanylate cyclase stimulator. |
体外活性 | Vericiguat inhibits the U46619-induced contractions of porcine coronary artery rings concentration-dependently (IC50: 956 nM). Vericiguat inhibits phenylephrine-induced contractions of rabbit saphenous artery rings, rabbit aortic rings, and canine femoral vein rings concentration-dependently (IC50: 798, 692, and 3072 nM, respectively). Vericiguat (0.01 μM to 100 μM) stimulates recombinant sGC concentration-dependently, by 1.7-fold to 57.6-fold. When combined with the NO donor diethylamine/nitric oxide complex, Vericiguat and DEA/NO have a synergistic effect on the enzyme activity over a wide range of concentrations. At the highest concentrations of Vericiguat (100 μM) and DEA/NO (100 nM), the specific activity of sGC is 341.6-fold above baseline. Vericiguat stimulates the sGC reporter cell line concentration-dependently (EC50: 1005±145 nM) [1]. |
体内活性 | Vericiguat causes a significant and dose-dependent increase in survival rates. Chronic oral treatment with Vericiguat (3 or 10 mg/kg, q.d.) results in a significant attenuation of blood pressure increase during the course of the study. Vericiguat (3 or 10 mg/kg) treatment leads to a significant reduction in kidney injury molecule Kim-1 and osteopontin expression which are used as biomarkers for renal injury and dysfunction. In the 3 and 10 mg/kg q.d. treatment groups, the rat survival rate is 70% and 90%, respectively, at the study end [1]. |
别名 | 维利西呱, BAY1021189 |
分子量 | 426.38 |
分子式 | C19H16F2N8O2 |
CAS No. | 1350653-20-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (105.54 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3453 mL | 11.7266 mL | 23.4533 mL | 58.6331 mL |
5 mM | 0.4691 mL | 2.3453 mL | 4.6907 mL | 11.7266 mL | |
10 mM | 0.2345 mL | 1.1727 mL | 2.3453 mL | 5.8633 mL | |
20 mM | 0.1173 mL | 0.5863 mL | 1.1727 mL | 2.9317 mL | |
50 mM | 0.0469 mL | 0.2345 mL | 0.4691 mL | 1.1727 mL | |
100 mM | 0.0235 mL | 0.1173 mL | 0.2345 mL | 0.5863 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vericiguat 1350653-20-1 GPCR/G Protein Guanylate cyclase Inhibitor inhibit 维利西呱 BAY 1021189 BAY1021189 Guanylate Cyclase BAY-1021189 inhibitor